Maximum Recommended Daily Dose of CONCERTA (Extended-Release Methylphenidate)
CONCERTA maximum recommended daily dose is 72 mg/day in adults (18-65 years). [1] CONCERTA maximum recommended daily dose is 54 mg/day in children aged 6-12 years and is 72 mg/day in adolescents aged 13-17 years. [1]
Short-Acting Methylphenidate Booster Dose When CONCERTA Effects Wane
A CONCERTA pharmacokinetic comparison included immediate-release (short-acting) methylphenidate as 5 mg doses given three times daily every 4 hours to approximate early immediate-release fluctuations. [1] In that comparison, the short-acting booster dose used was 5 mg immediate-release methylphenidate per booster dose. [1]
Medication Selection Algorithm
CONCERTA dosing is determined by titration of extended-release methylphenidate once daily in the morning. [1] When a short-acting “booster” is used to address medication-wearoff, the short-acting formulation corresponds to the immediate-release methylphenidate dosing studied alongside CONCERTA fluctuations (5 mg). [1]
Treatment Initiation Thresholds
CONCERTA should be initiated at 18 mg/day for children and adolescents and at 18 or 36 mg/day for adults. [1] Dose increases should occur in 18 mg increments at weekly intervals for patients without an optimal response at a lower dose. [1]
Targets or Goals of Therapy
Dose adjustment is used to achieve an optimal response with acceptable tolerability. [1]
Common Pitfalls to Avoid
CONCERTA daily dosage above 54 mg/day in children aged 6-12 years is not recommended. [1] CONCERTA daily dosage above 72 mg/day in adolescents and adults is not recommended. [1] CONCERTA should be taken once daily in the morning and must be swallowed whole without chewing, dividing, or crushing. [1]
Practical Dosing Limits for a Booster Strategy
A short-acting booster dose supported in the CONCERTA pharmacokinetic comparison is 5 mg immediate-release methylphenidate per additional dose. [1] Total daily dosing limits for CONCERTA still apply to the extended-release component, and extended-release and immediate-release regimens should be coordinated to remain within approved maximums for the CONCERTA product. [1]